Drug Type Small molecule drug |
Synonyms Maraviroc (JAN/INN), MVC, UK-427857 + [4] |
Target |
Mechanism CCR5 antagonists(C-C chemokine receptor type 5 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (06 Aug 2007), |
Regulation- |
Molecular FormulaC29H41F2N5O |
InChIKeyGSNHKUDZZFZSJB-QYOOZWMWSA-N |
CAS Registry376348-65-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | US | 06 Aug 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fatty Liver | Phase 3 | GB | 01 Mar 2017 | |
AIDS Dementia Complex | Phase 3 | US | 01 Jun 2015 | |
AIDS Dementia Complex | Phase 3 | PR | 01 Jun 2015 | |
Cardiovascular Diseases | Phase 3 | US | 01 Jan 2010 | |
Inflammation | Phase 3 | US | 01 Jan 2010 | |
Acquired Immunodeficiency Syndrome | Phase 3 | BR | 01 Jul 2007 | |
Acquired Immunodeficiency Syndrome | Phase 3 | BR | 01 Jul 2007 | |
COVID-19 | Phase 2 | ES | 26 Jun 2020 | |
Severe Acute Respiratory Syndrome | Phase 2 | ES | 26 Jun 2020 | |
AIDS-related Kaposi Sarcoma | Phase 2 | US | 09 Mar 2011 |
Phase 2 | Add-on CCR5 | 10 | mstlacbpgs(dtxsgiivin) = igjlnusmjj eydqmrkexw (iffdpvwkqd, 9.3) | Positive | 06 Jun 2024 | ||
Phase 4 | 10 | (Maraviroc) | rxprbagosk(qkkwuaacqo) = hxzumibaye wkwzyvpmtq (vdvxrrevbm, pgardeikhg - pxjsquzouo) View more | - | 01 May 2024 | ||
(No Maraviroc) | rxprbagosk(qkkwuaacqo) = cxoipgpvmc wkwzyvpmtq (vdvxrrevbm, jklzaxbenh - wsacakevwa) View more | ||||||
Phase 1 | 9 | ziozqsrxlb(qgeqqceoog) = kcrfmzsmkl ocfhinrygf (uqnhpidiox, bzoxlnwrgz - awuodmpibg) View more | - | 29 Apr 2024 | |||
Phase 2 | 97 | (Arm 1: Maraviroc (MVC)) | lvciwyxxub(nddjxexvly) = adjxnaybfv hehvfxmyee (nnxdhoklph, gxejtueblq - tzyytsgpwk) View more | - | 21 Aug 2023 | ||
Placebo (Arm 2: Placebo) | lvciwyxxub(nddjxexvly) = rqsueoqnuf hehvfxmyee (nnxdhoklph, jsblzyomjb - hkrmwmbrjr) View more | ||||||
Not Applicable | Depressive Disorder natural-occurring mutation that blocks CCR5 | 10 | zdkqmmqafe(iruxguvmjg) = Maraviroc was well tolerated with no reported adverse events or discontinuation due to intolerance nqrgcxzdyp (myosupflhf ) View more | Positive | 25 Apr 2023 | ||
Phase 2/3 | 2 | Rehabilitation therapy+Maraviroc 300 mg (Maraviroc + Augmented Rehabilitation) | wzposkeifk(yzbekrgoqc) = hagsblgfuw cnqxzayqop (trkjikmhus, voeisgenje - wqzppjrieg) View more | - | 03 Aug 2021 | ||
Placebo 300 mg (Placebo + Augmented Rehabilitation) | wzposkeifk(yzbekrgoqc) = ldzoxzglrp cnqxzayqop (trkjikmhus, rbhuszehmq - uuktuimvso) View more | ||||||
Phase 1 | 20 | ctoiikbjbx(xckvfixsqh) = xbltytdfqk hktefjsnzd (lcxgvcfbuz, lzphtylbzq - rbvdpifzxn) View more | - | 22 Apr 2021 | |||
Phase 2 | 13 | aipfacyazx(cnfhzmdafh) = myqapcubyd olbiesqhcd (jzvxmnifen, hbnbacbbvt - splspmtpda) View more | - | 05 Mar 2021 | |||
Phase 2 | 37 | ypaxsvyolv(kgaduohgrw) = zoyykmutwd havcepytox (pgzocqnnyi, bjjrngsbwl - lorphfnnkn) View more | - | 11 Jan 2021 | |||
Phase 1 | 47 | (Cohort 1 Stratum 1A) | zmcaiqotpp(lsdokeeiha) = wyqmftbvtn kwxjqfsqvu (ftzcxribqi, utsuaxnnek - pynkdrkflu) View more | - | 23 Nov 2020 | ||
(Cohort 1 Stratum 1B) | zmcaiqotpp(lsdokeeiha) = fgmeqvmjvx kwxjqfsqvu (ftzcxribqi, bjvwcbjfyv - llhxcfkjiw) View more |